BGI counter sues Illumina for patent infringement

A US subsidiary of Chinese genome sequencing company BGI has filed a patent infringement counterclaim against Illumina.

The claim, filed September 30 at the US District Court for the Northern District of California, alleges that Illumina is using a number of gene sequencers which infringe a patent (US number 9,944,984) owned by BGI’s US-based subsidiary, Complete Genomics.

The allegedly infringing sequencers are NovaSeq 6000, HiSeq X Ten, HiSeq 3000, and HiSeq 4000.

According to the filing, the patent covers BGI's proprietary “patterned array” technology. BGI said its “patterned array” technology is one of the underlying technologies for high-throughput, high-quality gene sequencing.

The company is seeking damages and an injunction which would require Illumina to stop selling the products.

The counter claim comes after Illumina sued BGI and its US affiliate Complete Genomics for patent infringement on September 18. Illumina alleged that the groups were infringing two of its patents (US numbers 7,566,537 and 9,410,200) for its DNA sequencing technology.

Illumina said BGI had started its commercialisation of the technology in China, outside the reach of US patent law, but was now importing its alleged infringing sequencers into the US.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Genetics

Illumina wins PTAB appeal over Columbia DNA patents

2 February 2021 Biotech company Illumina has won a dispute with Columbia University, after the Court of Appeals for the Federal Circuit backed an earlier ruling that the university’s DNA-sequencing patents were invalid.

Big Pharma

BGI secures appeal trial over Illumina DNA verdict

25 February 2021 Chinese genome sequencing company BGI has been given the go-ahead to appeal an English High Court ruling in an ongoing lawsuit launched by competitor Illumina regarding its DNA sequencing patents.

Medtech

BGI didn’t infringe one Illumina patent, fails to invalidate another

2 September 2021 The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial.